Cleveland BioLabs, a drug discovery and development company, has made a number of changes in corporate management responsibilities.

Michael Fonstein, Ph.D., has stepped down as CEO, but will continue to serve as president of Cleveland BioLabs with a primary focus on advancing the CBLB502 program toward FDA licensure as a countermeasure for Acute Radiation Syndrome. He will also guide business development opportunities and support recently established joint ventures.

Yakov Kogan, Ph.D., MBA, current COO of Cleveland BioLabs, has also been appointed interim CEO and will lead and coordinate the company's strategic and operational activities.

C. Neil Lyons, CPA, current CFO, will add to his duties oversight of investor and public relations activities.